Angiogenesis factors

Internal Medicine

Volumn 40, Issue 7, 2001, Pages 565-572

  Kuwano, Michihiko ^a   Fukushi, Jun Ichi ^a   Okamoto, Masahiro ^a   Nishie, Akihiro ^a   Goto, Hisatsugu ^a   Ishibashi, Tatsuro ^a   Ono, Mayumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Antiangiogenic drugs; Dormant factors; Neovascularization; Oxygen stress; Stroma cells; Vasculogenesis

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; CILENGITIDE; COMBRETASTATIN A4; ENDOSTATIN; EPHRIN; EPHRIN B2; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; K 22584; MARIMASTAT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; PRINOMASTAT; REBIMASTAT; SURAMIN; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ATHEROSCLEROSIS; CANCER; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG TARGETING; EMBRYO DEVELOPMENT; EYE DISEASE; HEMANGIOBLAST; HUMAN; HUMAN CELL; KNOCKOUT GENE; META ANALYSIS; MOUSE; NONHUMAN; PATHOLOGICAL ANATOMY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN DEGRADATION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL; VASCULAR ENDOTHELIUM;

EID: 0034873351     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.565     Document Type: Review

References (57)

1. Risau W, Sariola H, Zerwes HG, et al. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development 102:471-478, 1988.
2. Flamme I, Risau W. Induction of vasculogenesis and hematopoiesis in vitro. Development 116: 435-439, 1992.
3. Asahara T, Chen D, Takahashi T, et al. TIE2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Cire Res 83: 233-240, 1998.
4. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995.
5. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66, 1995.
6. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk 1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89: 981-990, 1997.
7. Wang HU, Chen ZF, Andersen DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93: 741-753, 1998.
8. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180, 1996.
9. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169, 1996.
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
11. Matsuda T, Okamura K, Sato Y, et al. Decreased response to epidermal growth factor during cellular senescence in cultured human microvascular endothelial cells. J Cell Physiol 150: 510-516, 1992.
12. Sato Y, Okamura K, Morimoto A, et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 204: 223-229, 1993.
13. Ono M, Okamura K, Nakayama Y, et al. Induction of human microvascular endothelial tubular morphogenesis by human keratinocytes: involvement of transforming growth factor-alpha. Biochem Biophys Res Commun 189:601-609, 1992.
14. Okamura K, Morimoto A, Hamanaka R, et al. A model system for tumor angiogenesis: involvement of transforming growth factor-alpha in tube formation of human microvascular endothelial cells induced by esophageal cancer cells. Biochem Biophys Res Commun 186: 1471-1479, 1992.
15. Ito K, Ryuto M, Ushiro S, et al. Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on Matrigel. J Cell Physiol 162: 213-224, 1995.
16. Oikawa T, Sasaki M, Inose M, et al. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. Anticancer Res 17: 1881-1886, 1997.
17. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17: 4015-4023, 1997.
18. Fukushi J, Morisaki T, Shono T, et al. Novel biological functions of interleukin-4: formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo. Biochem Biophys Res Commun 250: 444-448, 1998.
19. Abe T, Okamura K, Ono M, et al. Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. J Clin Invest 92: 54-61, 1993.
20. Ono M, Kawahara N, Goto D, et al. Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Cancer Res 56: 1512-1516, 1996.
21. Shono T, Motoyama M, Tatsumi K, et al. A new synthetic matrix metalloproteinase inhibitor modulates both angiogenesis and urokinase type plasminogen activator activity. Angiogenesis 2: 319-329, 1998/1999.
22. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74, 1995.
23. Dumont DJ, Gradwohl G, Fong GH, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897-1909, 1994.
24. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for TIE2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
25. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153: 1459-1466, 1998.
26. Lampugnani MG, Resnati M, Raiteri M, et al. A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol 118: 1511-1522, 1992.
27. Breier G, Breviario F, Caveda L, et al. Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system. Blood 87: 630-641, 1996.
28. DeLisser HM, Christofidou-Solomidou M, Strieter RM, et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151: 671-677, 1997.
29. Shono T, Ono M, Izumi H, et al. Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 16: 4231-4239, 1996.
30. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
31. Namiki A, Brogi E, Kearney M, et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270: 31189-31195, 1995.
32. Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 271: 25492-25497, 1996.
33. Akiri G, Nahari D, Finkelstein Y, et al. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17: 227-236, 1998.
34. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14: 34-44, 2000.
35. Polverini PJ. Role of the macrophage in angiogenesis-dependent diseases. Exs 79: 11-28, 1997.
36. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Luekoc Biol 55: 410-422, 1994.
37. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625-4629, 1996.
38. Toi M, Ueno T, Matsumoto H, et al. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 5: 1131-1137, 1999.
39. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 5: 1107-1113, 1999.
40. Torisu H, Ono M, Kiryu H, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1 alpha. Int J Cancer 85: 182-188, 2000.
41. Ono M, Torisu H, Fukushi J, et al. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol. 43 Suppl: 69-71, 1999.
42. Ryuto M, Ono M, Izumi H, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 271: 28220-28228, 1996.
43. Goto H, Kohno K, Sone S, et al. Gamma interferon-dependent induction of thymidine phosphorylase/platelet derived endothelial growth factor through gamma-activated sequence-like element in human macrophages. Cancer Res 61: 469-473, 2001.
44. Eady RA, Cowen T, Marshall TF, et al. Mast cell population density, blood vessel density and histamine content in normal human skin. Br J Dermatol 100: 623-633, 1979.
45. Artuc M, Hermes B, Steckelings UM, et al. Mast cells and their mediators in cutaneous wound healing - active participants or innocent bystanders? Exp Dermatol 8: 1-16, 1999.
46. 206. Mol Biol Cell 9: 875-884, 1998.
47. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346: 274-276, 1990.
48. Moller A, Lippert U, Lessmann D, et al. Human mast cells produce IL-8. J Immunol 151: 3261-3266, 1993.
49. Fukushi J, Ono M, Morikawa W, et al. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. J Immunol 165: 2818-2823, 2000.
50. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692, 1996.
51. O'Reilly MS, BoehmT, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
52. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
53. Morikawa W, Yamamoto K, Ishikawa S, et al. Angiostatin generated by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 275: 38912-38920, 2000.
54. Ozaki H, Yu AY, Della N, et al. Hypoxia inducible factor-1 alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci. 40: 182-189, 1999.
55. Danis RP, Bingaman DP, Jirousek M, et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 39: 171-179, 1998.
56. Murata T, Nagai R, Ishibashi T, et al. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 40: 764-769, 1997.
57. Nickoloff BJ, Mitra RS, Varani J, et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144: 820-828, 1994.